273 related articles for article (PubMed ID: 26491062)
1. Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.
Wiebelhaus JM; Walentiny DM; Beardsley PM
J Pharmacol Exp Ther; 2016 Jan; 356(1):43-52. PubMed ID: 26491062
[TBL] [Abstract][Full Text] [Related]
2. Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence.
Liu J; Schulteis G
Pharmacol Biochem Behav; 2004 Sep; 79(1):101-8. PubMed ID: 15388289
[TBL] [Abstract][Full Text] [Related]
3. Some determinants of morphine effects on intracranial self-stimulation in rats: dose, pretreatment time, repeated treatment, and rate dependence.
Altarifi AA; Negus SS
Behav Pharmacol; 2011 Oct; 22(7):663-73. PubMed ID: 21921839
[TBL] [Abstract][Full Text] [Related]
4. Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats.
Faunce KE; Banks ML
Exp Clin Psychopharmacol; 2020 Feb; 28(1):44-54. PubMed ID: 31008640
[TBL] [Abstract][Full Text] [Related]
5. The antagonistic activity profile of naloxone in μ-opioid receptor agonist-induced psychological dependence.
Nakamura A; Yasufuku K; Shimada S; Aritomi H; Furue Y; Chiba H; Muramoto M; Takase K; Koike K; Matsumoto T; Shimada T; Watari R; Matsuzaki T; Asaki T; Kanemasa T; Fujita M
Neurosci Lett; 2020 Sep; 735():135177. PubMed ID: 32569809
[TBL] [Abstract][Full Text] [Related]
6. Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats.
Leri F; Burns LH
Pharmacol Biochem Behav; 2005 Oct; 82(2):252-62. PubMed ID: 16182352
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Stinus L; Cador M; Zorrilla EP; Koob GF
Neuropsychopharmacology; 2005 Jan; 30(1):90-8. PubMed ID: 15138444
[TBL] [Abstract][Full Text] [Related]
8. In rats, acute morphine dependence results in antagonist-induced response suppression of intracranial self-stimulation.
Easterling KW; Holtzman SG
Psychopharmacology (Berl); 2004 Sep; 175(3):287-95. PubMed ID: 15024547
[TBL] [Abstract][Full Text] [Related]
9. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
10. Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure.
Altarifi AA; Rice KC; Negus SS
Behav Pharmacol; 2013 Sep; 24(5-6):459-70. PubMed ID: 23881045
[TBL] [Abstract][Full Text] [Related]
11. Validation and characterization of oxycodone physical dependence in C57BL/6J mice.
Carper M; Contreras KM; Walentiny DM; Beardsley PM; Damaj MI
Eur J Pharmacol; 2021 Jul; 903():174111. PubMed ID: 33901461
[TBL] [Abstract][Full Text] [Related]
12. Intracranial self-stimulation in rats: sensitization to an opioid antagonist following acute or chronic treatment with mu opioid agonists.
Easterling KW; Holtzman SG
J Pharmacol Exp Ther; 1997 Apr; 281(1):188-99. PubMed ID: 9103497
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic profile of ITI-333: a novel molecule for treatment of substance use disorders.
Snyder GL; Li P; Martin T; Zhang L; Yao W; Zheng H; Maguire DR; Gerak LR; Vanover KE; France CP; Davis R
Psychopharmacology (Berl); 2024 Jul; 241(7):1477-1490. PubMed ID: 38710856
[TBL] [Abstract][Full Text] [Related]
14. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling.
Wang HY; Friedman E; Olmstead MC; Burns LH
Neuroscience; 2005; 135(1):247-61. PubMed ID: 16084657
[TBL] [Abstract][Full Text] [Related]
15. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
Dodu JC; Moncayo RK; Damaj MI; Schlosburg JE; Akbarali HI; O'Brien LD; Kendall DA; Wu Z; Lu D; Lichtman AH
J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats.
Altarifi AA; Yuan Y; Zhang Y; Selley DE; Negus SS
Psychopharmacology (Berl); 2015 Feb; 232(4):815-24. PubMed ID: 25178814
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Abuse Potential Assessment of Flibanserin: Effects on Intracranial Self-Stimulation in Female and Male Rats.
Lazenka MF; Blough BE; Negus SS
J Sex Med; 2016 Mar; 13(3):338-49. PubMed ID: 26831817
[TBL] [Abstract][Full Text] [Related]
18. The highly selective dopamine D
Jordan CJ; Humburg B; Rice M; Bi GH; You ZB; Shaik AB; Cao J; Bonifazi A; Gadiano A; Rais R; Slusher B; Newman AH; Xi ZX
Neuropharmacology; 2019 Nov; 158():107597. PubMed ID: 30974107
[TBL] [Abstract][Full Text] [Related]
19. Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats.
Freitas K; Carroll FI; Negus SS
Exp Clin Psychopharmacol; 2016 Feb; 24(1):65-75. PubMed ID: 26461167
[TBL] [Abstract][Full Text] [Related]
20. Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in rats.
Altarifi AA; Miller LL; Negus SS
Behav Pharmacol; 2012 Oct; 23(7):678-92. PubMed ID: 22914074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
